Shots:

• The comparison study led to assessing of Nucala (mepolizumab)- Fasenra (benralizumab)- Cinqair (reslizumab) in patients aged ≥12 yrs with similar blood eosinophil counts for the treatment of severe eosinophilic asthma
• Results: Nacula 100mg SC reduces clinically significant exacerbations (34% to 45% vs Fasenra 30mg) and (45% vs Cinqair 3mg/kg) in ≥400 cells/μL based on ACQ guidelines
• Nacula is been evaluated in 3-000 patients in 16 clinical trials and approved in US- EU and in over 20 other markets. It is currently being evaluated for severe hypereosinophilic syndrome- nasal polyposis and COPD

 Ref: GSK | Image: GSK